← FDA Drug Approvals (Drugs@FDA)
ATORVALIQ
NDA · New Drug Application · Sponsor: CMP DEV LLC · Approved 2023-02-01
Drug application
- FDA Application #
NDA213260- Application type
- New Drug Application
- Brand name
- ATORVALIQ
- Generic name
- ATORVALIQ
- Active ingredients
- ATORVASTATIN CALCIUM
- Dosage form
- SUSPENSION
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- CMP DEV LLC
- Manufacturer
- CMP Pharma, Inc.
- First approval
- 2023-02-01
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown